 SHELTON, Conn., Sept. 22, 2021 PRNewswire -- NanoViricides, Inc. NYSE American: NNVC the Company, a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today on the significant advantages gained by remdesivir encapsulation within its lead COVID-19 candidate NV-CoV-2 thereby resulting in the dual-acting drug candidate NV-CoV-2-R with the promise of a potential pan-coronavirus cure. 